Minims (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride works by reversibly blocking voltage‑gated sodium channels in peripheral nerve membranes of the eye. This inhibition prevents the initiation and propagation of nerve impulses, resulting in loss of sensation on the ocular surface and providing rapid, short‑lasting anesthesia.

The appropriate dose of Minims is determined by the prescribing eye‑care professional based on the specific procedure and patient needs. The prescriber will decide the number of drops, frequency, and duration of treatment, ensuring safe and effective use.

Safety data for oxybuprocaine hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To order Minims, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Minims (oxybupracaine) is an ester‑type local anesthetic offering rapid onset and short duration of action, similar to tetracaine but with a slightly lower risk of systemic toxicity. Compared with amide‑type anesthetics such as lidocaine, oxybuprocaine provides comparable efficacy for surface anesthesia while having a distinct metabolic pathway.

Minims should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture. Ensure the cap is tightly closed to prevent contamination, and keep it out of reach of children.

Minims is applied topically to the eye as a sterile drop. The prescriber typically instills one or more drops onto the conjunctival sac, allowing the solution to spread over the ocular surface. The patient should keep the eye closed briefly to enhance drug contact before proceeding with the intended procedure.

Serious risks, though rare, include corneal epithelial toxicity, severe allergic reactions such as anaphylaxis, persistent elevation of intra‑ocular pressure, and vision loss. Any signs of severe irritation, swelling, or visual changes should prompt immediate medical evaluation.

Minims should not be used in individuals with a known hypersensitivity to oxybuprocaine, other ester‑type anesthetics, or any component of the formulation. Caution is also advised for patients with active corneal infections, severe epithelial defects, or uncontrolled glaucoma, where alternative anesthesia may be preferable.